Evidence map›Paper›PMID 41264131›Full record

ReviewMetabolic brain disease2025

The role of metabolomics in stroke: biomarkers of diagnosis and therapy.

Youyu Wang, Qi Tian, Mingchang Li

Abstract readReview
PubMed Publisher
In one paragraph

Review in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Youyu Wang *Department of Neurosurgery, Renmin Hospital of Wuhan University, 99 Ziyang Road, Wuhan, Hubei Province, 430060, China.
Qi Tian *Department of Neurosurgery, Renmin Hospital of Wuhan University, 99 Ziyang Road, Wuhan, Hubei Province, 430060, China.
Mingchang LiDepartment of Neurosurgery, Renmin Hospital of Wuhan University, 99 Ziyang Road, Wuhan, Hubei Province, 430060, China. mingcli@whu.edu.cn.

Funding

National Natural Science Foundation of China 8247050960Open Project of Hubei Key Laboratory 2023KFZZ017
6 · The paper itself

Abstract

Stroke is a neurological condition caused by an acute focal injury to the central nervous system, typically resulting from vascular events such as cerebral infarction, intracerebral hemorrhage, or subarachnoid hemorrhage. It is associated with high rates of incidence, disability, recurrence, and mortality. To reduce stroke-related mortality, researchers worldwide have developed various in vitro and in vivo models to study molecular mechanisms at different levels, including genes, microRNAs, and proteins, to identify biomarkers for improved diagnosis, treatment, and prognosis. Metabolomics, an emerging field derived from genomics and proteomics, plays a crucial role in understanding stroke pathophysiology. Changes in the metabolome can reflect the body's physiological state following a stroke. Numerous studies have identified biomarkers that aid in stroke diagnosis and treatment by analyzing metabolic alterations in vivo or in vitro stroke models. This article reviews the causes, diagnosis, and treatment of stroke, the role of metabolomics in stroke research, and the clinical significance of some biomarkers discovered by metabolomics for clinical work.

Indexed as

BiomarkersMetabolomicsStrokeAnimalsHumansBiomarkersBiomarkersClinical translationMetabolic alterationsMetabolomicsStroke

Identifiers

PMID41264131

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.